Prospective Bladder Cancer Infrastructure (ProBCI)
Launched by PROSPECTIVE BLADDER CANCER INFRASTRUCTURE FOUNDATION · Aug 4, 2020
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
The Prospective Bladder Cancer Infrastructure (ProBCI) trial is studying different types of bladder cancer in patients across the Netherlands. Specifically, it focuses on high-risk cases that are not advanced (non-muscle-invasive), advanced but still treatable (muscle-invasive), and those that have spread to other parts of the body (metastatic). This research aims to gather important information about these conditions to improve future treatments and care for bladder cancer.
If you or someone you know has bladder cancer that is at any stage except for the very early stage (Ta), you may be eligible to participate in this trial as long as you are 18 years or older and can provide written consent. There are no other specific reasons that would prevent someone from joining. Participants in this study can expect to contribute to valuable research while still being able to take part in other studies if they choose. Your involvement could help advance the understanding and treatment of bladder cancer for many others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Bladder cancer
- • Any stage except Ta
- • 18 years or older
- • Written informed consent
- Exclusion Criteria:
- • No exclusion criteria
- • Note: participation in ProBCI does not exclude the patient from participation in other studies.
About Prospective Bladder Cancer Infrastructure Foundation
The Prospective Bladder Cancer Infrastructure Foundation is a dedicated clinical trial sponsor focused on advancing research and treatment options for bladder cancer. By fostering collaboration among healthcare professionals, researchers, and patients, the Foundation aims to build a robust infrastructure for studying bladder cancer's epidemiology, treatment modalities, and patient outcomes. Through innovative clinical trials and comprehensive data collection, the Foundation seeks to enhance understanding of bladder cancer and improve therapeutic strategies, ultimately contributing to better patient care and outcomes in this critical area of oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ede, , Netherlands
Utrecht, , Netherlands
Nijmegen, , Netherlands
Breda, , Netherlands
Amersfoort, , Netherlands
Rotterdam, , Netherlands
Maastricht, , Netherlands
Arnhem, , Netherlands
Venlo, , Netherlands
Groningen, , Netherlands
Leeuwarden, , Netherlands
Zwolle, , Netherlands
Dordrecht, , Netherlands
'S Hertogenbosch, , Netherlands
Amsterdam, , Netherlands
Leiderdorp, , Netherlands
Hoofddorp, , Netherlands
Sittard, , Netherlands
Tilburg, , Netherlands
Almelo, , Netherlands
Tilburg, , Netherlands
Nijmegen, , Netherlands
Emmen, , Netherlands
Winterswijk, , Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials